SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Feb 27, 2020
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Feb. 27, 2020 · CIK: 0001385818 · Accession: 0000000000-20-001798
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236599
Letter
February 27, 2020 Joshua Disbrow Chief Executive Officer Aytu Biosciences, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Re:Aytu Bioscience, Inc. Registration Statement on Form S-3 Filed February 24, 2020 File No. 333-236599 Dear Mr. Disbrow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 27, 2020
Joshua Disbrow
Chief Executive Officer
Aytu Biosciences, Inc.
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
Re:Aytu Bioscience, Inc.
Registration Statement on Form S-3
Filed February 24, 2020
File No. 333-236599
Dear Mr. Disbrow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences